Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya63813510.26442/00403660.2026.02.203529ReviewsОбзорыReview ArticleA new paradigm of the pathogenesis of primary sclerosing cholangitis associated with ulcerative colitis: microbiota and system intestine-liver. A reviewМикробиота и система «кишечник – печень»: новая парадигма патогенеза первичного склерозирующего холангита, ассоциированного с язвенным колитомhttps://orcid.org/0000-0003-2195-9643SbikinaEvgenia S.СбикинаЕвгения Сергеевна
Russian Federation

канд. мед. наук, ст. науч. сотр. отд. гепатологии

esbikina@gmail.comhttps://orcid.org/0000-0002-0344-8375VinnitskayaElena V.ВинницкаяЕлена Владимировна
Russian Federation

д-р мед. наук, зав. отд. гепатологии

esbikina@gmail.comhttps://orcid.org/0000-0002-9782-4860ParfenovAsfold I.ПарфеновАсфольд Иванович
Russian Federation

д-р мед. наук, проф., зав. отд. патологии кишечника

esbikina@gmail.comLoginov Moscow Clinical Scientific CenterГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы07032026982Issues of gastroenterologyВопросы гастроэнтерологии1191242510202426122025Copyright ©; 2026, Consilium MedicumCopyright ©; 2026, ООО "Консилиум Медикум"2026Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/638135

The close relationship between primary sclerosing cholangitis and ulcerative colitis has given rise to a number of hypotheses aimed at deciphering their pathogenesis from the standpoint of bidirectional connections involving immune, endocrine and inflammatory mechanisms. The review examines the main directions of the concept of the "gut-liver axis" from the point of view of the pathogenetic relationships of primary sclerosing cholangitis associated with ulcerative colitis and intestinal microbiota.

Тесная связь первичного склерозирующего холангита и язвенного колита породила ряд гипотез, направленных на расшифровку их патогенеза с позиций двунаправленных связей, включающих иммунные, эндокринные и воспалительные механизмы. В обзоре рассмотрены основные направления концепции оси «кишечник – печень» с точки зрения патогенетических взаимосвязей первичного склерозирующего холангита, ассоциированного с язвенным колитом и микробиотой кишечника.

primary sclerosing cholangitisulcerative colitismicrobiotanew paradigm of pathogenesisпервичный склерозирующий холангитязвенный колитмикробиотановая парадигма патогенезаEuropean Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761-806. DOI: 10.1016/j.jhep.2022.05.011Винницкая Е.В., Абдулхаков С.Р., Абдурахманов Д.Т., и др. Актуальные вопросы диагностики и лечения первичного склерозирующего холангита (по материалам российского консенсуса по диагностике и лечению первичного склерозирующего холангита. Москва, 2018 г.). Терапевтический архив. 2019;91(2):9-15 [Vinnitskaya EV, Abdulkhakov SR, Abdurakhmanov DT, et al. Important problems in the diagnosis and treatment of primary sclerosing cholangitis (based on the Russian consensus on diagnosis and treatment autoimmune hepatitis. Moscow, 2018). Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(2):9-15 (in Russian)]. DOI: 10.26442/00403660.2019.02.000075Хатьков И.Е., Винницкая Е.В., Ефанов М.Г., и др. Первичный склерозирующий холангит. Взгляд терапевта и хирурга. Под ред. И.Е. Хатькова, Е.В. Винницкой. М.: Литтерра, 2019. 184 с. [Khat'kov IE, Vinnitskaia EV, Efanov MG, et al. Pervichnyi skleroziruiushchii kholangit. Vzgliad terapevta i khirurga. Pod red. IE Khat'kova, EV Vinnitskoi. Moscow: Litterra, 2019. 184 p. (in Russian)].Barberio B, Massimi D, Cazzagon N, et al. Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Gastroenterology. 2021;161(6):1865-77. DOI: 10.1053/j.gastro.2021.08.032Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181-88. DOI: 10.1016/j.jhep.2011.10.025Григорьева Г.А., Мешалкина Н.Ю. Болезнь Крона. М.: Медицина, 2007. 184 с. [Grigor'eva GA, Meshalkina NIu. Bolezn' Krona. Moscow: Meditsina, 2007. 184 p. (in Russian)].Weismüller TJ, Trivedi PJ, Bergquist A, et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology. 2017;152(8): 1975-1984.e8. DOI: 10.1053/j.gastro.2017.02.038Trivedi PJ, Crothers H, Mytton J, et al. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology. 2020;159(3):915-28. DOI: 10.1053/j.gastro.2020.05.049Khan N, Trivedi C, Shah Y, et al. The Natural History of Newly Diagnosed Ulcerative Colitis in Patients with Concomitant Primary Sclerosing Cholangitis. Inflamm Bowel Dis. 2018;24(9):2062-7. DOI: 10.1093/ibd/izy106Lundberg Båve A, Bergquist A, Bottai M, et al. Increased risk of cancer in patients with primary sclerosing cholangitis. Hepatol Int. 2021;15(5):1174-82. DOI: 10.1007/s12072-021-10214-6Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045-55. DOI: 10.1002/hep.26565Chapman RW. Primary sclerosing cholangitis – A long night's journey into day. Clin Liver Dis (Hoboken). 2022;20(Suppl. 1):21-32. DOI: 10.1002/cld.1264Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138(3): 1102-11. DOI: 10.1053/j.gastro.2009.11.046Ellinghaus D, Jostins L, Spain SL, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016;48(5):510-8. DOI: 10.1038/ng.3528Jiang X, Karlsen TH. Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat Rev Gastroenterol Hepatol. 2017;14(5):279-95. DOI: 10.1038/nrgastro.2016.154Ji SG, Juran BD, Mucha S, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49(2):269-73. DOI: 10.1038/ng.3745Bergquist A, Montgomery SM, Bahmanyar S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2008;6(8):939-43. DOI: 10.1016/j.cgh.2008.03.016van Munster KN, Bergquist A, Ponsioen CY. Inflammatory bowel disease and primary sclerosing cholangitis: One disease or two? J Hepatol. 2024;80(1):155-68. DOI: 10.1016/j.jhep.2023.09.031Thomas JP, Modos D, Rushbrook SM, et al. The Emerging Role of Bile Acids in the Pathogenesis of Inflammatory Bowel Disease. Front Immunol. 2022;13:829525. DOI: 10.3389/fimmu.2022.829525Симаненков В.И., Маев И.В., Ткачева О.Н., и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758 [Simanenkov VI, Maev IV, Tkacheva ON, et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758 (in Russian)]. DOI: 10.15829/1728-8800-2021-2758Парфенов А.И. Значение повышенной проницаемости кишечника в патогенезе внутренних болезней. Терапевтический архив. 2024;96(2):85-90 [Parfenov AI. The significance of increased intestinal permeability in the pathogenesis of internal diseases. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(2):85-90 (in Russian)]. DOI: 10.26442/00403660.2024.02.202587Быкова С.В., Сабельникова Е.А., Новиков А.А., и др. Зонулин и I-FABP – маркеры повреждения энтероцитов при целиакии. Терапевтический архив. 2022;94(4):511-6 [Bykova SV, Sabelnikova EA, Novikov AA, et al. Zonulin and I-FABP are markers of enterocyte damage in celiac disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(4):511-6 (in Russian)]. DOI: 10.26442/00403660.2022.04.201480Grant AJ, Lalor PF, Salmi M, et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet. 2002;359(9301):150-7. DOI: 10.1016/S0140-6736(02)07374-9Kim YS, Hurley EH, Park Y, Ko S. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis. Exp Mol Med. 2023;55(7):1380-87. DOI: 10.1038/s12276-023-01042-9Blesl A, Stadlbauer V. The Gut-Liver Axis in Cholestatic Liver Diseases. Nutrients. 2021;13(3):1018. DOI: 10.3390/nu13031018Chung H, Pamp SJ, Hill JA, et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell. 2012;149(7):1578-93. DOI: 10.1016/j.cell.2012.04.037Björnsson E, Cederborg A, Akvist A, et al. Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2005;40(9):1090-4. DOI: 10.1080/00365520510023288Tripathi A, Debelius J, Brenner DA, et al. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15(12):785. DOI: 10.1038/s41575-018-0031-8Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. 2017;66(4):611-9. DOI: 10.1136/gutjnl-2015-310500Little R, Wine E, Kamath BM, et al. Gut microbiome in primary sclerosing cholangitis: A review. World J Gastroenterol. 2020;26(21):2768-80. DOI: 10.3748/wjg.v26.i21.2768Rühlemann M, Liwinski T, Heinsen FA, et al. Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Aliment Pharmacol Ther. 2019;50(5):580-9. DOI: 10.1111/apt.15375Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65(10):1681-9. DOI: 10.1136/gutjnl-2015-311004Lemoinne S, Kemgang A, Ben Belkacem K, et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut. 2020;69(1):92-102. DOI: 10.1136/gutjnl-2018-317791Quraishi MN, Acharjee A, Beggs AD, et al. A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways. J Crohns Colitis. 2020;14(7):935-47. DOI: 10.1093/ecco-jcc/jjaa021Fuentes S, Rossen NG, van der Spek MJ, et al. Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation. ISME J. 2017;11(8):1877-89. DOI: 10.1038/ismej.2017.44Schrumpf E, Kummen M, Valestrand L, et al. The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation. J Hepatol. 2017;66(2):382-9. DOI: 10.1016/j.jhep.2016.09.020Tabibian JH, O'Hara SP, Trussoni CE, et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology. 2016;63(1):185-96. DOI: 10.1002/hep.27927Shalon D, Culver RN, Grembi JA, et al. Profiling the human intestinal environment under physiological conditions. Nature. 2023;617(7961):581-91. DOI: 10.1038/s41586-023-05989-7Liwinski T, Zenouzi R, John C, et al. Alterations of the bile microbiome in primary sclerosing cholangitis. Gut. 2020;69(4):665-72. DOI: 10.1136/gutjnl-2019-318416Rankin JG, Boden RW, Goulston SJ, Morrow W. The liver in ulcerative colitis; treatment of pericholangitis with tetracycline. Lancet. 1959;2(7112):1110-2. DOI: 10.1016/s0140-6736(59)90098-4Färkkilä M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40(6):1379-86. DOI: 10.1002/hep.20457Shah A, Crawford D, Burger D, et al. Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Semin Liver Dis. 2019;39(4):432-41. DOI: 10.1055/s-0039-1688501Begley M, Hill C, Gahan CG. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol. 2006;72(3):1729-38. DOI: 10.1128/AEM.72.3.1729-1738.2006Vrieze A, Out C, Fuentes S, et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol. 2014;60(4):824-31. DOI: 10.1016/j.jhep.2013.11.034Kitahara M, Sakata S, Sakamoto M, Benno Y. Comparison among fecal secondary bile acid levels, fecal microbiota and Clostridium scindens cell numbers in Japanese. Microbiol Immunol. 2004;48(5):367-75. DOI: 10.1111/j.1348-0421.2004.tb03526.xShah A, Macdonald GA, Morrison M, Holtmann G. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework. Am J Gastroenterol. 2020;115(6):814-22. DOI: 10.14309/ajg.0000000000000604Abarbanel DN, Seki SM, Davies Y, et al. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol. 2013;33(2):397-406. DOI: 10.1007/s10875-012-9801-1Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8(4):e60042. DOI: 10.1371/journal.pone.0060042Caraceni P, Vargas V, Solà E, et al. The Use of Rifaximin in Patients With Cirrhosis. Hepatology. 2021;74(3):1660-73. DOI: 10.1002/hep.31708Tabibian JH, Gossard A, El-Youssef M, et al. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. Am J Ther. 2017;24(1):e56-63. DOI: 10.1097/MJT.0000000000000102Damman JL, Rodriguez EA, Ali AH, et al. Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2018;47(7):886-95. DOI: 10.1111/apt.14540Allegretti JR, Kassam Z, Carrellas M, et al. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. Am J Gastroenterol. 2019;114(7):1071-79. DOI: 10.14309/ajg.0000000000000115Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019;4(3):492-503. DOI: 10.1038/s41564-018-0333-1Liao L, Schneider KM, Galvez EJC, et al. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. Gut. 2019;68(8):1477-92. DOI: 10.1136/gutjnl-2018-316670